Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 42, 2011, Pages 17444-17449

  Heinrichs, Daniel ^a   Knauel, Meike ^a   Offermanns, Christian ^a   Berres, Marie Luise ^a   Nellen, Andreas ^a   Leng, Lin ^b   Schmitz, Petra ^a   Bucala, Richard ^b   Trautwein, Christian ^a   Weber, Christian ^c   Bernhagen, Jürgen ^a   Wasmuth, Hermann E ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; CD74 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MACROPHAGE MIGRATION INHIBITION FACTOR; METFORMIN; RECOMBINANT CYTOKINE; RECOMBINANT MACROPHAGE MIGRATION INHIBITION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE DELETION; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; LIVER INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STELLATE CELL;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CARBON TETRACHLORIDE; GENE EXPRESSION; HEPATIC STELLATE CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTRAMOLECULAR OXIDOREDUCTASES; LIVER CIRRHOSIS, EXPERIMENTAL; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLATELET-DERIVED GROWTH FACTOR; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

MUS;

EID: 80054815328     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1107023108     Document Type: Article

References (47)

1. Schuppan D, Afdhal NH (2008) Liver cirrhosis. Lancet 371:838-851. (Pubitemid 351323895)
2. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States N Engl. J Med 340:745-750. (Pubitemid 29114292)
3. Ginès P, Cárdenas A, Arroyo V, Rodés J (2004) Management of cirrhosis and ascites. N Engl J Med 350:1646-1654.
4. Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669.
5. Friedman SL (2008) Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88(1):125-172.
6. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209-218. (Pubitemid 40385459)
7. Berres ML, et al. (2010) Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest 120:4129-4140.
8. Wasmuth HE, et al. (2009) Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 137:309-319, 319.e1-3.
9. Calandra T, Roger T (2003) Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol 3:791-800. (Pubitemid 37328657)
10. Schober A, Bernhagen J, Weber C (2008) Chemokine-like functions of MIF in atherosclerosis. J Mol Med (Berl) 86:761-770.
11. Bernhagen J, et al. (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365:756-759. (Pubitemid 23339882)
12. Calandra T, et al. (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6(2):164-170. (Pubitemid 30082360)
13. Baugh JA, et al. (2002) A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 3(3):170-176. (Pubitemid 38961128)
14. Morand EF, Leech M, Bernhagen J (2006) MIF: A new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 5:399-410.
15. Verschuren L, et al. (2009) MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ Res 105(1):99-107.
16. Bernhagen J, et al. (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13:587-596. (Pubitemid 46828480)
17. Zernecke A, Bernhagen J, Weber C (2008) Macrophage migration inhibitory factor in cardiovascular disease. Circulation 117:1594-1602. (Pubitemid 351440647)
18. Hoi AY, Iskander MN, Morand EF (2007) Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. Inflamm Allergy Drug Targets 6(3):183-190. (Pubitemid 47455787)
19. Hori Y, et al. (2003) Immunohistochemical study of macrophage migration inhibitory factor in rat liver fibrosis induced by thioacetamide. Eur J Histochem 47:317-324.
20. Tiegs G, Hentschel J, Wendel A (1992) A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 90:196-203.
21. Nakajima H, et al. (2006) Lack of macrophage migration inhibitory factor protects mice against concanavalin A-induced liver injury. Liver Int 26:346-351. (Pubitemid 43349326)
22. Miller EJ, et al. (2008) Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 451:578-582. (Pubitemid 351186266)
23. Qi D, et al. (2009) Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. J Clin Invest 119:3807-3816.
24. Ma H, et al. (2010) Impaired macrophage migration inhibitory factor-AMP-activated protein kinase activation and ischemic recovery in the senescent heart. Circulation 122:282-292.
25. Starlets D, et al. (2006) Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 107:4807-4816. (Pubitemid 43882632)
26. Leng L, et al. (2003) MIF signal transduction initiated by binding to CD74. J Exp Med 197:1467-1476. (Pubitemid 36686708)
27. Hardie DG (2003) Minireview: The AMP-activated protein kinase cascade: The key sensor of cellular energy status. Endocrinology 144:5179-5183.
28. Sahin H, Trautwein C, Wasmuth HE (2010) Functional role of chemokines in liver disease models. Nat Rev Gastroenterol Hepatol 7:682-690.
29. Jin J, et al. (2009) AMPK inhibitor Compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells. J Lipid Res 50:2389-2397.
30. Gregory JL, et al. (2004) Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice. Arthritis Rheum 50:3023-3034. (Pubitemid 39209542)
31. Gregory JL, et al. (2006) Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. J Immunol 177:8072-8079. (Pubitemid 44846325)
32. Vera PL, Iczkowski KA, Wang X, Meyer-Siegler KL (2008) Cyclophosphamide-induced cystitis increases bladder CXCR4 expression and CXCR4-macrophage migration inhibitory factor association. PLoS ONE 3:e3898.
33. Weber C, et al. (2008) Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc Natl Acad Sci USA 105: 16278-16283.
34. Hong F, et al. (2009) Hepatic stellate cells express functional CXCR4: Role in stromal cellderived factor-1alpha-mediated stellate cell activation. Hepatology 49:2055-2067.
35. Tachibana K, et al. (1998) The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393:591-594. (Pubitemid 28319250)
36. Zernecke A, et al. (2008) Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 102:209-217. (Pubitemid 351651125)
37. Maubach G, Lim MC, Kumar S, Zhuo L (2007) Expression and upregulation of cathepsin S and other early molecules required for antigen presentation in activated hepatic stellate cells upon IFN-gamma treatment. Biochim Biophys Acta 1773:219-231. (Pubitemid 46138003)
38. Lue H, et al. (2007) Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 26:5046-5059. (Pubitemid 47206949)
39. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL (2006) Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 177:8730-8739. (Pubitemid 44893839)
40. Meyer-Siegler KL, Leifheit EC, Vera PL (2004) Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer 4:34.
41. Meyer-Siegler KL, et al. (2007) Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun 8:646-652. (Pubitemid 350238434)
42. Adachi M, Brenner DA (2008) High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 47:677-685. (Pubitemid 351280736)
43. Caligiuri A, et al. (2008) Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. Hepatology 47:668-676. (Pubitemid 351280735)
44. Kamada Y, et al. (2003) Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125:1796-1807. (Pubitemid 37500444)
45. Xu A, et al. (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112(1):91-100. (Pubitemid 38056380)
46. Wasmuth HE, et al. (2009) The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB. Hepatology 49:775-780.
47. Zaldivar MM, et al. (2010) CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 51:1345-1353.